Genomic Health. The Redwood City, CA-based company (NASDAQ: GHDX) is widely admired in diagnostics because it proved to skeptical insurers that diagnostics aren’t just cheap commodities anymore—they provide information about health that’s quite valuable. Genomic Health has continued to thrive and grow under two CEOs—Randy Scott and Kim Popovits. It is now rolling out new iterations of its original OncotypeDx product that predict the risk of recurrence for patients with prostate and colon cancer, proving it’s not a one-hit wonder in breast cancer. By showing the way in molecular diagnostics, Genomic Health has inspired other entrepreneurs to think big about how new instruments can be used to better predict and prevent disease before doctors have to turn to high-priced and often-toxic therapies. The company could be highly profitable tomorrow if it wanted to be, but instead it chooses to get by on low margins while continuing to invest in the future. It’s a sure sign of a company with a view toward long-term excellence.
and speaking of investing in the future, GHI today participated in the $40MM fund raising effort by InVitae (~20% owned by GHI) Look up InVitae if you are not familiar. Founded by and run by GHI founder Randy Scott, they are working on a single assay that will include everything in the over 3000 assays currently out there....for about $1000 per test.
stock price waivers from day to day and week to week but follow the science.....this stock is going much much higher in the future....great company for building long term wealth.